Recombinant HRP Anti-C7 antibody [EPR7036] (ab205857)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EPR7036] to C7
- Suitable for: WB
- Reacts with: Human
- Conjugation: HRP
Overview
-
Product name
HRP Anti-C7 antibody [EPR7036]
See all C7 primary antibodies -
Description
HRP Rabbit monoclonal [EPR7036] to C7 -
Host species
Rabbit -
Conjugation
HRP -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human C7 aa 800 to the C-terminus. The exact sequence is proprietary.
Database link: P10643 -
Positive control
- WB : HepG2, K562 and HUVEC whole cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR7036 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
Our Abpromise guarantee covers the use of ab205857 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | 1/5000. Detects a band of approximately 94 kDa (predicted molecular weight: 94 kDa). |
Target
-
Function
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C7 serves as a membrane anchor. -
Involvement in disease
Defects in C7 are a cause of complement component 7 deficiency (C7D) [MIM:610102]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. -
Sequence similarities
Belongs to the complement C6/C7/C8/C9 family.
Contains 1 EGF-like domain.
Contains 1 LDL-receptor class A domain.
Contains 1 MACPF domain.
Contains 2 Sushi (CCP/SCR) domains.
Contains 2 TSP type-1 domains. -
Post-translational
modificationsC7 has 28 disulfide bridges. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 730 Human
- Entrez Gene: 109828 Mouse
- Entrez Gene: 117517 Rat
- Omim: 217070 Human
- SwissProt: P10643 Human
- Unigene: 78065 Human
- Unigene: 208034 Mouse
- Unigene: 232711 Rat
-
Alternative names
- C7 antibody
- CO7_HUMAN antibody
- complement component 7 antibody
- Complement component C7 antibody
Images
-
All lanes : HRP Anti-C7 antibody [EPR7036] (ab205857) at 1/5000 dilution
Lane 1 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lane 2 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
Lane 3 : HUVEC (Human Umbilical Vein Endothelial Cell) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 94 kDa
Observed band size: 94 kDa
Exposure time: 16 minutesThis blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab205857 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
References (0)
ab205857 has not yet been referenced specifically in any publications.